We are live on ! Find out more
OTLK icon

Outlook Therapeutics
OTLK

17 hedge funds and large institutions have $4.96M invested in Outlook Therapeutics in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

0% more funds holding

Funds holding: 17 → 17 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0.02% less ownership

Funds ownership: 0.12% → 0.1% (-0.02%)

20% less capital invested

Capital invested by funds: $6.16M → $4.96M (-$1.21M)

Holders
17
Holders Change
–
Holders Change %
0%
% of All Funds
0.39%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
1
Increased
6
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
+$40.8K
2
TSS
Two Sigma Securities
New York
+$35.9K
3
Citadel Advisors
Citadel Advisors
Florida
+$31.9K
4
PAM
Panagora Asset Management
Massachusetts
+$30.7K
5
UBS Group
UBS Group
Switzerland
+$5.81K

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$730K
2
SM
Sabby Management
Florida
-$395K
3
VF
Virtu Financial
New York
-$1.04K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$2.7M -$395K -1,904 -13%
ACA
2
Avoro Capital Advisors
New York
$889K – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$397K – – –
MWNA
4
Marshall Wace North America
New York
$340K – – –
BCM
5
Bridgeway Capital Management
Texas
$179K – – –
PAM
6
Panagora Asset Management
Massachusetts
$109K +$30.7K +148 +39%
Bank of America
7
Bank of America
North Carolina
$54K +$40.8K +197 +313%
TSS
8
Two Sigma Securities
New York
$51K +$35.9K +173 +234%
BlackRock
9
BlackRock
New York
$41K +$1.66K +8 +4%
CAM
10
Cormorant Asset Management
Massachusetts
$40K -$730K -3,521 -95%
ACP
11
Acuta Capital Partners
California
$38K – – –
VF
12
Virtu Financial
New York
$37K -$1.04K -5 -3%
Citadel Advisors
13
Citadel Advisors
Florida
$32K +$31.9K +154 New
Morgan Stanley
14
Morgan Stanley
New York
$21K +$415 +2 +2%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$14K – – –
UBS Group
16
UBS Group
Switzerland
$9K +$5.81K +28 +187%
ASN
17
Advisory Services Network
Georgia
$3K – – –

OTLK Hedge Fund Activity: Q4 2017 in Review

17 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q4 2017, worth a combined $4.96M — down 20% from $6.16M a quarter earlier.

Fund positioning in OTLK was balanced in Q4 2017: 1 fund opened new positions, 1 closed out, 6 added to existing stakes and 3 trimmed.

The largest buyer was Bank of America, adding an estimated $40.8K. The largest seller was Cormorant Asset Management, cutting an estimated $730K.

  • 17 institutional investors held Outlook Therapeutics (OTLK) as of Q4 2017, unchanged from Q3 2017.
  • Funds reported $4.96M of Outlook Therapeutics stock for Q4 2017, down 20% quarter-over-quarter.
  • 1 fund opened new Outlook Therapeutics positions in Q4 2017 and 1 closed out, a net change of 0 holders.
  • The largest Outlook Therapeutics buyer in Q4 2017 was Bank of America, an estimated $40.8K added.
  • The largest Outlook Therapeutics seller in Q4 2017 was Cormorant Asset Management, an estimated $730K sold.

Based on aggregated 13F filings for Q4 2017.